| Autor: |
Pichler FB; Confluence Health Consulting, Sydney, NSW, Australia., Boysen M; National Institute for Health and Care Excellence (NICE), London, UK., Mittmann N; Canadian Agency for Drugs and Technologies in Healthcare, Ottawa, ON, Canada., Gilardino R; MSD, Zurich, Switzerland., Bruce A; Amgen, Sydney, NSW, Australia., Bond K; Institute of Health Economics, Edmonton, AB, Canada., Vreman RA; Roche, Utrecht, Netherlands., Largeron N; Sanofi, Paris, France., Banhazi J; Menarini, Zurich, Switzerland., Ollendorf DA; Tufts Medical Center, Institute for Clinical Research and Health Policy Studies, Boston, MA, USA., Jain M; BioMarin, London, UK., Upadhyaya S; Life Sciences Consultant, London, UK., Goettsch WG; Zorginstituut Nederland (ZIN), Utrecht, Netherlands. |
| Abstrakt: |
Operationalization guidance is needed to support health technology assessment (HTA) bodies considering implementing lifecycle HTA (LC-HTA) approaches. The 2022 Health Technology Assessment International (HTAi) Global Policy Forum (GPF) established a Task Force to develop a position paper on LC-HTA. In its first paper, the Task Force established a definition and framework for LC-HTA in order to tailor it to specific decision problems. This second paper focused on the provision of practical operational guidance to implement LC-HTA. Detailed descriptions of the three LC-HTA operational steps are provided (defining the decision problem, sequencing of HTA activities, and developing optimization criteria) and accompanied by worked examples and an operationalization checklist with 20 different questions for HTA bodies to consider when developing an LC-HTA approach. The questions were designed to be applicable across different types of HTA and scenarios, and require adaptation to local jurisdictions, remits, and context. |
